CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-12 | Schott Robert J. SVP, Head of Development | Shares withheld for taxes | −5,463 | $5.76 | $31K | 34,537 |
| 2021-12-28 | BIOGEN INC. 10% owner | Sale | −2,764 | $8.51 | $24K | 24,152,466 |
| 2021-12-27 | BIOGEN INC. 10% owner | Sale | −600 | $8.56 | $5K | 24,155,230 |
| 2021-12-23 | BIOGEN INC. 10% owner | Sale | −81,187 | $8.55 | $695K | 24,155,830 |
| 2021-12-09 | BIOGEN INC. 10% owner | Sale | −23,660 | $8.56 | $203K | 24,237,017 |
| 2021-12-08 | BIOGEN INC. 10% owner | Sale | −75,814 | $8.64 | $655K | 24,260,677 |
| 2021-12-07 | BIOGEN INC. 10% owner | Sale | −52,178 | $8.52 | $444K | 24,336,491 |
| 2021-12-02 | BIOGEN INC. 10% owner | Sale | −1,874 | $8.51 | $16K | 24,388,669 |
| 2021-12-01 | BIOGEN INC. 10% owner | Sale | −730 | $8.52 | $6K | 24,390,543 |
| 2021-11-26 | BIOGEN INC. 10% owner | Sale | −28,884 | $8.60 | $248K | 24,391,273 |
| 2021-10-29 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −140 | $8.12 | $1K | 54,455 |
| 2021-08-13 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award | +7,500 | 54,595 | ||
| 2021-08-13 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-25 | McClung David Mark EVP, Chief Business Officer | Shares withheld for taxes | −11,525 | $12.02 | $139K | 129,294 |
| 2021-06-11 | Duraibabu Prathyusha SVP, CFO, PFO and PAO | Grant or award | +7,500 | 49,827 | ||
| 2021-06-11 | Duraibabu Prathyusha SVP, CFO, PFO and PAO | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-04-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Shares withheld for taxes | −811 | $11.71 | $9K | 62,496 |
| 2021-04-25 | Duraibabu Prathyusha VP, PFO and PAO | Shares withheld for taxes | −662 | $11.71 | $8K | 40,128 |
| 2021-03-25 | Duraibabu Prathyusha VP, PFO and PAO | Shares withheld for taxes | −345 | $12.27 | $4K | 40,790 |
| 2021-03-25 | Duraibabu Prathyusha VP, PFO and PAO | Shares withheld for taxes | −345 | $12.27 | $4K | 40,790 |
Page 15 of 17 · 338 trades